Theravance Biopharma (TBPH) Misses Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update
May 9, 2017 4:05 PM EDTDUBLIN, May 9, 2017 /PRNewswire/ --Â Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the first quarter ended March 31, 2017. Revenue for the first quarter of 2017 was $3.1 million. The first quarter operating loss was $58.8 million, or $48.5 million excluding non-cash share-based compensation expense of $10.3 million. Cash, cash equivalents, and marketable securities totaled $540.7 million as of March 31, 2017.
Rick E Winningham, Chairman and Chief Executive Officer, commented: "As we progress into mid-2017, we are on track... More
